The expanding public health threat of obesity and overweight.

Obesity and overweight is a continuing public health crisis. This health threat respects no boundaries or economic strata, and is a pervasive universal threat with short- and long-term negative sequelae associated. Pharmacists and other health professionals need to structure interventions from individual patient and population-based standpoints. Documentation of effects of programmes needs to be disseminated and incorporated into educational, research and practice-based efforts.

Negative Consequences of the Widespread and Inappropriate Easy Access to Purchasing Prescription Medications on the Internet.

BACKGROUND: The purchase of prescription medications via the Internet is a global phenomenon with significant economic, social, and health-related impacts. The growth of online purchasing of prescription medicines is significant and has been amplified by social isolation related to the COVID-19 pandemic, with many patients unable to obtain medicines as they normally would. By contrast, there are licensed, certified, legitimate retail pharmacies that provide significant and vital services to patients. OBJECTIVE: To review the major public health threat from illegal entities that sell any type of prescription medicines to individuals without proper physician oversight. DISCUSSION: Rogue and inappropriate online vendors are providing counterfeit and substandard medications fraudulently with untold impacts on morbidity and mortality globally. This article presents the differentiation between the types of legal and illegal Internet pharmacies, as well as the actions that are currently in play to affect the illegal online purchase of prescription medicines. Much must be done in a collaborative, global effort to address the public health threat of obtaining prescription drugs via the Internet. CONCLUSION: Global, federal, state, health professional, societal, and patient-specific collaborations are necessary to affect the significant threat that is now present via the increasing ease of access to online medication purchases.

Physician office vs retail clinic: patient preferences in care seeking for minor illnesses.

PURPOSE: Retail clinics are a relatively new phenomenon in the United States, offering cheaper and convenient alternatives to physician offices for minor illness and wellness care. The objective of this study was to investigate the effects of cost of care and appointment wait time on care-seeking decisions at retail clinics or physician offices. METHODS: As part of a statewide random-digit-dial survey of households, adult residents of Georgia were interviewed to conduct a discrete choice experiment with 2 levels each of 4 attributes: price ($59; $75), appointment wait time (same day; 1 day or longer), care setting-clinician combination (nurse practitioner in retail clinic; physician in private office), and acute illness (urinary tract infection [UTI]; influenza). The respondents indicated whether they would seek care under each of the 16 resulting choice scenarios. A cooperation rate of 33.1% yielded 493 completed telephone interviews. RESULTS: The respondents preferred to seek care for both conditions; were less likely to seek care for UTI (beta = -0.149; P = .008); preferred to seek care from a physician (beta = 1.067; P < .001) and receive same day care (beta = -2.789; P < .001). All else equal, cost savings of $31.42 would be required for them to seek care at a retail clinic and $82.12 to wait 1 day or more. CONCLUSIONS: Time and cost savings offered by retail clinics are attractive to patients, and they are likely to seek care there given sufficient cost savings. Appointment wait time is the most important factor in care-seeking decisions and should be considered carefully in setting appointment policies in primary care practices.

Marketing of patent medicines in the nineteenth century via a corkscrew medicine spoon.

The C. T. Williamson spoon with manufactured products from a pharmaceutical company engraved on the bowl of the spoon is one of the earliest examples of a manufacturer marketing products via a drug delivery device. The Burroughs, Wellcome and Company, a British corporation using initially an American patented, and later a British patented, Williamson corkscrew spoon marketed British manufactured medicinal products in the U.S. and England to physicians and pharmacists in the late nineteenth and early twentieth century. Other corkscrew spoons were manufactured in this era without product specific notations contained on the spoons. 40 These corkscrew spoons, such as the Williamson and Noe patented apparatuses, helped patients in more easily consuming liquid medications. They also were items potentially favored by physicians and pharmacists for patient's pro- vided liquid medications. Finally, they allowed patients to open corked containers, consume liquid dosage amounts, and hopefully more appropriately comply with necessary regimens in the late nineteenth and early twentieth century. Not surprisingly, Burroughs, Wellcome and Company used the Williamson spoon to successfully market company products to physicians, pharmacists, and patients on several continents.

An unusual personalized cough mixture from the early twentieth century.

There is no way at this point to determine the financial or marketing impact of the personalized cough mixture upon the Randall Drug Store. Nor can there be an estimate of the influence that the likeness of Dr. Randall's daughter on the label might have had upon sales or use of the product. However, in an era of uncertainty and naiveté regarding health options in general and medicinal products in particular, it could be assumed that this photograph-adorned personalized cough mixture bottle would have been promoted in-store by Dr. Randall with confidence, and used with assurance by purchasers. This uniquely presented cough mixture was no doubt a point of pride for the pharmacist, as well as his lovely daughter.

Cannabis for Chronic Pain: Challenges and Considerations.

The National Academies of Sciences, Engineering, and Medicine has found substantial evidence that cannabis (plant) is effective for the treatment of chronic pain in adults, and moderate evidence that oromucosal cannabinoids (extracts, especially nabiximols) improve short-term sleep disturbances in chronic pain. The paradoxical superiority of the cannabis plant over cannabinoid molecules represents a challenge for the medical community and the established processes that define modern pharmacy. The expanding and variable legalization of cannabis in multiple states nationwide represents an additional challenge for patients and the medical community because recreational and medicinal cannabis are irresponsibly overlapped. Cannabis designed for recreational use (containing high levels of active ingredients) is increasingly available to patients with chronic pain who do not find relief with current pharmacologic entities, which exposes patients to potential harm. This article analyzes the available scientific evidence to address controversial questions that the current state of cannabis poses for health care professionals and chronic pain patients and sets the basis for a more open discussion about the role of cannabis in modern medicine for pain management. A critical discussion on these points, the legal status of cannabis, and considerations for health care providers is presented.

The "Next Dose" dosage spoon circa 1927 as an aid for proper dose measurement and enhancement of medication compliance.

These "Next Dose" spoons were marketed until the 1960s in the United States. Unfortunately, the further paths crossed by Messieurs Morgan and Bushey cannot be further elucidated. Nor can further information be identified for the eventual marketer of the "Next Dose" spoon. What we can surmise is that the use of specialized devices to administer and remind patients about dosing is not new. There is scant mention of compliance in the literature too years ago, but pharmacies and patients no doubt found these devices to be useful. For the pharmacist, advertising on the spoon provided a reminder of their services, and for the patient, a reminder was present on the body of the spoon to remind them of the next dosing time. Most medications during this time were in liquid form, and a device to help accurately measure liquid, elixir, tonic, suspensions was a highly sought-after item welcomed by patients and/or caregivers.

Patterns of ACE inhibitor use in elderly medicaid patients with heart failure.

The authors identified 321 elderly Kansas Medicaid patients with congestive heart failure and examined angiotensin-converting enzyme (ACE) inhibitor use. Using retrospective claims data, ACE inhibitor use was quantified and daily doses compared to a target enalapril-equivalent dose of 20 mg. The cohort patients averaged 80 years of age, 84% were female, and 70% resided primarily in a nursing home. Only 37.8% received an ACE inhibitor. Users were younger than nonusers (t=2.00; p=0.046), but there was no gender difference (odds ratio [OR], 1.4; 95% confidence interval [CI], 0.73, 2.6). ACE inhibitor users averaged eight prescriptions annually, providing approximately 257 medication days (70% of the study period). The average enalapril-equivalent daily dose was 10.6 mg, and only 22% received the target dose. Nursing home residents were less likely to receive an ACE inhibitor than ambulatory patients (OR, 0.55; 95% CI, 0.34, 0.89) but equally likely to receive target doses (OR, 1.3; 95% CI, 0.34, 4.9). ACE inhibitor use in the Kansas Medicaid congestive heart failure population is not consistent with practice guidelines, particularly among older and/or nursing home patients.

The importance of survey research standards.

Every discipline within fields of research has instituted guidelines and templates for research endeavors and subsequent publications of findings, with the ultimate result being an increase in quality and acceptance by researchers within and across disciplines. These significant efforts are by nature ongoing, as well they should. These enhancements and guideline developments have been instituted in basic science disciplines, clinical pharmacy, and pharmacy administration relevant and related to subsequent scholarly publication of research findings. Specific research endeavors have included bench research, clinical trials and randomized clinical trials, meta analyses, outcomes research, and large scale database analyses. A similar need for quality and standardization also exists for survey research and scholarship. The purpose of this paper is to clarify why this is important and crucial for the Journal and our academy.

Associations between communication climate and the frequency of medical error reporting among pharmacists within an inpatient setting.

OBJECTIVE: Although error-reporting systems enable hospitals to accurately track safety climate through the identification of adverse events, these systems may be underused within a work climate of poor communication. The objective of this analysis is to identify the extent to which perceived communication climate among hospital pharmacists impacts medical error reporting rates. METHODS: This cross-sectional study used survey responses from more than 5000 pharmacists responding to the 2010 Hospital Survey on Patient Safety Culture (HSOPSC). Two composite scores were constructed for "communication openness" and "feedback and about error," respectively. Error reporting frequency was defined from the survey question, "In the past 12 months, how many event reports have you filled out and submitted?" Multivariable logistic regressions were used to estimate the likelihood of medical error reporting conditional upon communication openness or feedback levels, controlling for pharmacist years of experience, hospital geographic region, and ownership status. RESULTS: Pharmacists with higher communication openness scores compared with lower scores were 40% more likely to have filed or submitted a medical error report in the past 12 months (OR, 1.4; 95% CI, 1.1-1.7; P = 0.004). In contrast, pharmacists with higher communication feedback scores were not any more likely than those with lower scores to have filed or submitted a medical report in the past 12 months (OR, 1.0; 95% CI, 0.8-1.3; P = 0.97). CONCLUSIONS: Hospital work climates that encourage pharmacists to freely communicate about problems related to patient safety is conducive to medical error reporting. The presence of feedback infrastructures about error may not be sufficient to induce error-reporting behavior.

Patients' view of retail clinics as a source of primary care: boon for nurse practitioners?

PURPOSE: To estimate consumer utilities associated with major attributes of retail clinics (RCs). DATA SOURCES: A discrete choice experiment (DCE) with 383 adult residents of the metropolitan statistical areas in Georgia conducted via Random Digit Dial survey of households. The DCE had two levels each of four attributes: price ($59; $75), appointment wait time (same day; 1 day or more), care setting-provider combination (nurse practitioner [NP]-RC; physician-private office), and acute illness (urinary tract infection; influenza), resulting in 16 choice scenarios. The respondents indicated whether they would seek care under each scenario. CONCLUSIONS: Cost savings and convenience offered by RCs are attractive to urban patients, and given sufficient cost savings they are likely to seek care there. All else equal, one would require cost savings of at least $30.21 to seek care from an NP at RC rather than a physician at private office, and $83.20 to wait one day or more. IMPLICATIONS FOR PRACTICE: Appointment wait time is a major determinant of care-seeking decisions for minor illnesses. The size of the consumer utility associated with the convenience feature of RCs indicates that there is likely to be further growth and employment opportunities for NPs in these clinics.